Cross-agency comparison: 🇬🇧 MHRA leads with 32 documents in 90 days

FDA vs EMA vs MHRA vs Health Canada — who's most active?

The volume pattern suggests that the UK and US environments are currently the most active, with MHRA and FDA generating more frequent regulatory output than EMA and Health Canada, which may indicate faster-moving expectations and more near-term guidance churn in those markets. Sponsors should consider that multi-market filing strategies may need the most iterative regulatory monitoring and cross-functional bandwidth for UK/US dossiers, while the lower output from EMA and Health Canada could suggest somewhat less frequent change but not necessarily lower complexity. In practical terms, this points to prioritizing regulatory intelligence and submission readiness resources where the pace of updates is highest, so global plans can absorb divergent signals without forcing late-stage dossier rework.